The Telmisartan Effectiveness on Left ventricular MAss Reduction (TELMAR) trial will assess the effect of the angiotensin II (Ang II) receptor blocker, telmisartan, on left ventricular hypertrophy (LVH) compared with the β-blocker, metoprolol, at similar antihypertensive doses. The rationale is that antihypertensives reduce LVH, a cardiac adaptation to pressure overload, principally by pressure-related effects. Ang II plays a key role in pressure-independent mechanisms causing LVH, and angiotensin-converting enzyme (ACE) inhibitors induce more pronounced LVH regression than some other antihypertensives. Blocking Ang II Type 1 receptors may be more effective than ACE inhibition in reducing LVH. TELMAR is a prospective, randomised, double-blind, double-dummy, parallel-group trial. A total of 140 patients (age 18-80 years) with uncontrolled essential hypertension (mean daytime systolic blood pressure [SBP] >140 mmHg or diastolic blood pressure [DBP] >90 mmHg and/or night-time SBP >120 mmHg or DBP >70 mmHg, measured by ambulatory blood pressure monitoring [ABPM]) and left ventricular mass index related to height (LVMI) >0.8 g/cm for females, >1.1 g/cm for males (defined by magnetic resonance imaging [MRI]) will be randomised to once-daily telmisartan or metoprolol. The telmisartan dose will be 40 mg for the first two weeks, 80 mg for 5.5 months and 40 mg for the last two weeks. Metoprolol will be given at a dose of 47.5 mg for two weeks, 95 mg for 5.5 months and 47.5 mg for two weeks. Concomitant add-on medication with hydrochlorothiazide and amlodipine will be allowed. The primary endpoint is the percentage change in LVMI at treatment end versus baseline, using MRI. Secondary variables include blood pressure changes and response rates assessed by ABPM and manual cuff sphygmomanometry, and end-systolic wall stress, systolic left ventricular function (LVF) and diastolic LVF determined by MRI. A separate study was performed prior to the main trial to define the normal range of MRI data in an age-matched population.
Introduction
Left ventricular hypertrophy (LVH), as the major mechanism of cardiac adaptation to pressure overload, is independently associated with an increased rate of cardiovascular mortality and morbidity, including stroke, congestive heart failure and coronary artery disease. 1, 2 The prevalence of LVH in patients with hypertension has been estimated to be between 9% and 61%. 3, 4 LVH correlates with inadequate blood pressure (BP) control, 5 and patients with both LVH and hypertension have up to nine times the incidence of cardiac events than patients who have hypertension only.Thus, LVH is to be regarded as the most powerful predictor of clinical prognosis in patients with arterial hypertension.
Effects of antihypertensive therapy on left ventricular hypertrophy
It is well established that antihypertensive therapy, by lowering BP, can reverse LVH. 6, 7 However, it is becoming apparent that the LVH regression induced by some antihypertensive agents is greater than would be expected from the magnitude of the BP reduction. For example, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II (Ang II) receptor blockers (ARBs) produce greater reductions in left ventricular mass (LVM) than β-blockers, despite similar antihypertensive efficacy. 8, 9 The impact of β-blockers may be less pronounced because their effects are mainly confined to pressure-related mechanisms, whereas ACE inhibitors (ACE-Is) and ARBs may cause LVH regression through additional mechanisms unrelated to BP.
Ang II, the principal effector molecule of the renin-angiotensin-aldosterone system (RAAS), plays a central role in the pressure-independent mechanisms leading to LVH. 10 It is a potent growth stimulus for cardiomyocytes and vascular smooth muscle cells. Increasing evidence also suggests that local cardiac Ang II, generated by enzymes other than ACE, is an important part of the signalling cascade and contributes to the hypertrophic response to pressure overload.
Both ACE-Is and ARBs lower BP by inhibiting the action of Ang II. ACE-Is also appear to be Paper Friedrich particularly effective in reducing LVH in hypertensive patients. 11 However, ACE-Is do not block the RAAS completely, due to compensatory stimulation of alternative, ACE-independent, local tissue pathways of Ang II formation. 12 Because ARBs act by selectively blocking Ang II Type 1 (AT 1 )-receptors (i.e., the final step of the RAAS), they inhibit all of the actions of Ang II whether it is produced systemically or by separate pathways in local tissue. Therefore, ARBs may be more effective in regressing LVH than ACE inhibition.Thus, the class of ARBs looks promising. In clinical studies, these agents have been shown to reduce not only LVM, 13, 14 but also cardiovascular morbidity and mortality more effectively than atenolol, despite a similar reduction in BP. 15 
Telmisartan
Telmisartan is an orally active, non-peptide AT 1receptor blocker. 16 The antihypertensive effect of once-daily telmisartan in patients with mild-to-moderate hypertension results in a significant reduction of supine, seated and standing systolic BP (SBP) and diastolic BP (DBP), usually without orthostatic change. 16 At the starting dose of 40 mg once-daily, telmisartan reduces SBP/DBP by an average of 11.3/7.3 mmHg. If target BP is not achieved with telmisartan 40 mg, the dose can be increased to 80 mg; this dose reduces SBP/DBP by an average of 13.7/8.1 mmHg in patients with mild-to-moderate hypertension.A clear antihypertensive response is seen within 1 hour after administration of the first dose of telmisartan and is maintained for the full 24-hour dosing interval. 17 Trough-to-peak ratios for telmisartan are >85% for DBP and >80% for SBP. 17 In addition, in ambulatory BP monitoring (ABPM) studies, a once-daily dose of telmisartan, 40 mg or 80 mg, consistently lowered BP over the entire 24hour dosing interval. [18] [19] [20] [21] [22] Short-and long-term clinical trials indicate that telmisartan is well-tolerated in patients with mild-to-moderate essential hypertension, with a side-effect profile similar to that of placebo. 16, 22, 23 The effectiveness of losartan, valsartan, irbesartan and candesartan cilexetil in reducing LVM has already been reported, 13, 14, [24] [25] [26] suggesting that this is a class effect of ARBs. Evidence from preclinical and small clinical studies indicates that telmisartan shares this property, although it has yet to be confirmed in a large-scale clinical trial.
Rationale for effect of telmisartan on left ventricular hypertrophy
Since LVH is related to 24-hour BP, [27] [28] [29] [30] the provision by telmisartan of BP control throughout the entire interval between doses might be expected to produce greater LVH regression than agents whose antihypertensive efficacy tapers off towards the end of the dosing interval. The long duration of action of telmisartan can be attributed to its pharmacokinetic profile: it has a half-life of approximately 24 hours, 31 binds tightly to the AT 1receptor and is released slowly with a low drug-receptor dissociation constant, 32 and it is highly lipophilic. 33 A lipophilic compound will readily permeate the plasma membrane, allowing it to bind to intracellular proteins. This proteinbound drug is released gradually over time. Furthermore, because telmisartan has a high volume of distribution (500 L), 34 it will disperse readily into the tissue compartment, thereby increasing the size of the intracellular proteinbound reservoir.
Telmisartan and left ventricular hypertrophy -preclinical evidence
There are several reasons to expect that telmisartan will reduce LVH effectively. Firstly, in in vitro experiments, pre-treatment of cultured rat cardiac fibroblasts with telmisartan (10 -7 M) completely inhibited the usual Ang II-induced increase in collagen production and secretion by these cells. 35 In contrast, pre-treatment with an AT 2 -receptor blocker had no effect on collagen synthesis.Thus, by selectively blocking the AT 1 -receptor, but not the AT 2 -receptor, telmisartan should decrease cardiac fibrosis in vivo.
Studies in animals have also shown that treatment with telmisartan significantly reduces left ventricular weight. Telmisartan has demonstrated beneficial effects in transgenic TGR(mREN2)27 rats, 36 hypertensive diabetic rats, 37 spontaneously hypertensive rats 38 and mice. 39
Telmisartan and left ventricular hypertrophy -clinical evidence
Several clinical investigations suggest that telmisartan also induces LVH regression in patients with hypertension ( Table 1 ).
The effect of telmisartan monotherapy on cardiac structure has been examined in a group of 18 patients with essential hypertension. 40 Telmisartan was given for 24 weeks at a once-daily dose of 40 mg, with up-titration to 80 mg if necessary. The reductions in SBP (from 160+12 mmHg at baseline to 132+21 mmHg at study end [p<0.01]) and DBP (from 100+6 mmHg to 84+10 mmHg [p<0.01]) were accompanied by a significant reduction in echocardiographic left ventricular mass index (LVMI) (from 128+36 g/m 2 at baseline to 117+24 g/m 2 at treatment end [p<0.05]). There was also a slight, but non-significant, improvement in diastolic function, as reflected by an increase in the early to atrial filling (E/A) ratio from 0.98+0.05 to 1.02+0.07.
Another echocardiographic follow-up study has examined the effect of telmisartan, 40-80 mg monotherapy, in 80 patients, 43-62 years of age, with mild-to-moderate LVH and essential hypertension. 41 After 12 months of telmisartan treatment, mean SBP was reduced from 143.5+10 mmHg to 126+8 mmHg (p<0.001), and DBP from 98.3+8 mmHg to 86+7 mmHg (p<0.001). There was a concomitant decrease in LVMI, from 120.8+7 g/m 2 to 110.1+3 g/m 2 (p<0.01). Furthermore, the reduction in LVMI resulting from telmisartan monotherapy was associated with a significant improvement in diastolic filling. That the provision of 24-hour BP control with telmisartan is associated with LVH regression has been demonstrated in a study involving 24 patients, 37-69 years of age, with mild-to-moderate hypertension and LVH. 43 After 24 weeks of treatment with telmisartan 40-80 mg, mean daytime and night-time ambulatory DBP and SBP had declined significantly from baseline (by 10.4-11.7%; p<0.01). Moreover, LVMI, as assessed by echocardiography, fell by 11%, from 152+5 g/m 2 at baseline to 135+6 g/m 2 at study end (p=0.02).
The effects of treatment with telmisartan 40 mg, ramipril 2.5 mg or a combination of the two drugs on LVMI have been compared in 75 middle-aged (40-59 years) patients with hypertension. 44 After six months of treatment, echocardiographically determined LVMI was reduced by 11.9% in patients receiving ramipril (n=25), 10.9% in patients receiving telmisartan (n=25), and 15.0% in patients receiving both ramipril and telmisartan (n=25). Thus, telmisartan 40 mg is as effective as ramipril 2.5 mg in producing LVH regression, with a combination of both drugs being even more effective. It remains to be established whether this latter finding is attributable to a greater antihypertensive effect or to more extensive blockade of the RAAS.
Using three-dimensional echocardiography, the effect of telmisartan on LVM was studied. 45 In this double-blind, randomised, multicentre study, 65 patients with hypertension received treatment with either telmisartan 80 mg (n=40; mean age 50+8 years) or hydrochlorothiazide (HCTZ) (n=25; mean age 52+5 years) for 12 months. Both drugs lowered BP significantly: mean 24-hour ambulatory SBP/DBP was reduced from baseline by 24/13 mmHg with telmisartan and by 10/8 mmHg with HCTZ. There was also a significant 16 g/m 2 decrease in LVMI (from 141+16 g/m 2 to 125+19 g/m 2 ; p<0.02) in the telmisartan treatment group. However, the 4 g/m 2 reduction in LVMI (from 139+20 g/m 2 to 135+22 g/m 2 ) observed in the HCTZ group was not statistically significant.
Finally, the long-term effects of telmisartan on LVMI and diastolic function have been investigated in 76 patients, 38-64 years of age, with previously untreated hypertension. 46 Two years of treatment with telmisartan 40-80 mg reduced BP by 23%, LVMI by 81% and E/A ratio by 72% compared with pre-treatment values.
Nevertheless, the previous studies suffer from a small sample size, especially given the fact, that the reproducibility of echocardiography is limited. 47, 48 Metoprolol Metoprolol was chosen as the comparative standard because of its broad use in clinical practice and favourable safety profile. It is recommended for the treatment of arterial hypertension and has been shown to be effective in reducing BP 49 and LVH. [50] [51] [52] 
Study objective
The Telmisartan Effectiveness on Left ventricular MAss Reduction (TELMAR) trial has been designed to assess the impact of the ARB telmisartan on LVMI versus standard β-blocker therapy with metoprolol over a treatment period of six months in patients with arterial hypertension. Since both treatment arms aim to control BP adequately, any selective effect of telmisartan or metoprolol on LVM beyond BP reduction will be elucidated. 
PAPER
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Dose selection
The dosage of metoprolol used in the TELMAR trial (95 mg once-daily) is recommended for patients with hypertension. 49, 53 Telmisartan 80 mg once-daily was selected, because it has been shown to be effective for BP reduction, without significant side effects. Metoprolol is used in even higher doses, but since BP control is not the primary endpoint in this study and will be titrated using concomitant medication, no effect on the results is to be expected.
Study design
The design of this prospective, randomised, double-blind, parallel-group, multicentre trial is depicted in Table 2 and Figure 1 .After a 10-day runin phase, patients will be randomised in a double-blind fashion to once-daily treatment for two weeks with either telmisartan 40 mg plus metoprolol placebo or metoprolol 47.5 mg plus telmisartan placebo. A forced up-titration will then be performed to once-daily telmisartan 80 mg or metoprolol 95 mg, respectively (plus matched placebo). This up-titration step was implemented to minimise sudden drops in BP and heart rate that can occur with β-blockers.Treatment with the full doses of telmisartan and metoprolol will continue for 5.5 months, since significant changes in LVM have been observed during this time-frame using ACE-Is as the therapeutic agent. 54 At the end of the 5.5-month treatment period, drug doses will be down-titrated to telmisartan 40 mg and metoprolol 47.5 mg for two weeks. Patients whose BP is adequately controlled (i.e., SBP <140 mmHg and DBP <90 mmHg) on blinded study medication at the follow-up visits will be scheduled for the next visits without any further change of medication. If, however, BP is still not controlled at Visit 5 (two weeks after complete titration of study medication), HCTZ 12.5 mg once-daily will be prescribed as add-on medication unless contraindications to HCTZ are present. If HCTZ is contraindicated, amlodipine 5 mg oncedaily should be given. If BP is still not controlled at six weeks from randomisation (Visit 6), patients on add-on HCTZ 12.5 mg once-daily will have the dose up-titrated to HCTZ 25 mg once-daily; patients uncontrolled on amlodipine 5 mg will be withdrawn from the trial. Patients on HCTZ 25 mg with uncontrolled BP after 12 weeks (Visit 7) will be prescribed amlodipine 5 mg once-daily as an add-on medication, unless contraindications to amlodipine are present. If amlodipine is contraindicated, the patient will be withdrawn from the trial. Treatment allocation will be determined according to a randomisation code, created by a commercial programme (ClinPro/LBL 5.2, Clinical Systems Inc.). Randomisation will be stratified by study centre. Access to the randomisation schedule is restricted to the Clinical Trial Support group, who generate the randomisation code and labels, and to the pharmaceutical department, where packaging takes place. Persons directly involved in the conduct and analysis of the trial have no access to the treatment allocation prior to database lock.
Selection of study sites
The TELMAR trial will be performed at 14 centres (12 hospitals and two private practices) in Germany, Italy and Switzerland. The selection of these centres was based on the capability of identifying patients with untreated hypertension (either ambulatory or hospitalised) and performing state-of-the-art cardiovascular magnetic resonance imaging (MRI) (i.e., they have access to a suitable 1.5T MRI system with appropriate cardiovascular software and are experienced in cardiovascular MRI procedures). Each of the 14 sites is expected to screen a sufficient number of subjects to enter 10 patients. 
Patients with contraindications to magnetic resonance imaging
-Implanted pacemaker or defibrillator -Implanted vascular clips -Gross obesity (i.e., weight >150 kg) G Specific exclusion for the disease under study -Known or suspected secondary hypertension -Known renal artery stenosis -Known endocrine disorders associated with secondary hypertension -Severe arterial hypertension, defined as a mean seated diastolic blood pressure >115 mmHg or a mean seated systolic blood pressure >200 mmHg -Patients with a complete loss of diurnal blood pressure (BP) variation, defined as the lack of a fall in BP during sleep or a drop of <5% compared with daily mean BP -Hypertrophic obstructive cardiomyopathy, clinically relevant aortic valve stenosis or clinically relevant mitral valve disease; vascular disease affecting blood pressure (coarctation; subclavian artery stenosis) G Specific concomitant therapy exclusions -Use of an angiotensin-converting enzyme inhibitor or an AT 1 -receptor blocker for more than two weeks within the last three months -Chronic administration of digoxin or other digitalis-type drugs, without regular monitoring of plasma levels 
Patient selection
Male and female Caucasian patients, aged 18-80 years, with untreated, mild-to-moderate essential hypertension (mean daytime SBP >140 mmHg or DBP >90 mmHg and/or night-time SBP >120 mmHg or DBP >70 mmHg, measured using ABPM) and evidence of LVH on MRI (LVM >0.9 g/cm for females, >1.2 g/cm for males) will be eligible for inclusion in the TELMAR trial.These cut-off values have been modified according to Lorenz et al., 55 in order to ensure the inclusion of LVH patients only.
The study population will be confined to untreated patients in order to avoid effects of previous drug therapy. Being aware of the challenge to identify treatment-naïve patients, great care was taken to select a sufficient number of centres with a suitable infrastructure to recruit these subjects. Table 3 shows the exclusion criteria for the TELMAR trial. If no exclusion criteria exist and the patient provides his/her written informed consent, the inclusion criteria for LVH and BP will be investigated (the complete inclusion criteria are listed in Table 4 ).The presence of LVH will be determined initially by echocardiography.The classification proposed by Vasan and coworkers 56 will be used to select patients with a sufficient probability of having LVH.Those with a wall thickness of LVH grade I-IV will then have their BP assessed by 24-hour ABPM. Patients will be discontinued at any time during the study for the reasons outlined in Table 5 . Compliance with the study protocol will be assessed by history and pill counts.
Exclusion criteria and eligibility

Efficacy assessments
The primary endpoint is the percentage change in LVMI related to height [LVMI(H)] at the end of treatment compared with baseline. Secondary endpoints include BP changes and percentage responses assessed by ABPM and manual cuff sphygmomanometry, and end-systolic wall stress, systolic left ventricular function (LVF) and diastolic LVF determined by MRI. To maximise sensitivity in measuring the study parameters, special care was taken to use reliable techniques to measure BP and LVM.
Seated blood pressure
Seated BP will be measured at screening, during MRI and at follow-up according to accepted guidelines. 57 Three measurements will be taken at intervals of at least 5 minutes; the lowest value will be taken into account.
Ambulatory blood pressure monitoring
Continuous ABPM will be conducted to assess the effects of treatment on BP since it shows a better correlation with LVH and cardiovascular complications than isolated clinic measurements. 29, 58 In addition, ABPM values are less likely to be affected by short-term external influences than clinic readings. ABPM for 24+2 hours will be performed at baseline and at the end of the 5.5-month full-dose treatment period using a standard monitoring device (SpaceLabs, Washington, USA). The cuff will be placed on the same arm during both evaluations.BP will be measured at 20-minute intervals during the daytime and at 30-minute intervals at night. The patient will be asked to record the timing of any disorders or special events using an 'event button' on the device. Patients will be assessed by ABPM on a day without any extraordinary stress. Distinct rules exist for the validity of single ABPM measurements, Inadequate blood pressure control, defined as seated mean diastolic blood pressure >90 mmHg or seated mean systolic blood pressure >140 mmHg at two consecutive visits (i.e., a regular visit plus an interim check) after forced up-titration of study medication and the addition of hydrochlorothiazide 25 mg and amlodipine 5 mg PAPER hourly means, time period means and the entire data set. All data editing will be performed in a blinded fashion; there will be no further editing once patient treatment assignments are known.
Magnetic resonance imaging MRI is a highly accurate and reproducible modality for the quantification of LVM. It is superior to echocardiography 59 and is very well suited for follow-up studies of LVM changes. 60 As the widely accepted gold standard, it allows for a marked sample size reduction of studies on LVM changes. 47, 48 Because body surface area is an independent predictor of left ventricular changes 61 and may be less predictive than a height-related index, 62 the TELMAR trial uses LVMI(H) instead of an index related to the body surface area. The patients will be prepared for gated MRI with leads placed in the standard position to ensure optimal tracing for gating. The largest amplitude tracing will be used for gating. Administration of sedative medication is left to the investigator's discretion; noise protection will be provided.A standard MRI procedure using a stateof-the-art sequence (steady-state-free-precession) will be used in dedicated cardiovascular MR systems equipped with a cardiac coil. After webbased image data transfer, an independent, blinded central read will be performed at a core laboratory specialising in cardiovascular MRI readings (CIRCLE Institute GmbH, Berlin, Germany) using certified software (MRI-MASS ® 5.0 and MRI-FLOW ® 3.0; MEDIS, Leiden,The Netherlands) and standard operator procedures with trabecular tissue included into the LVM. End-systolic wall stress (ESWS) will be calculated using the following formula:
Comparison of MRI-derived left ventricular mass data to normal values
Evidence of LVH on MRI, as defined in the inclusion criteria, is related to the published data of Lorenz et al. 55 The steady-state-free-precession MRI technique that will be applied in the TELMAR trial depicts trabecular tissue more accurately, 63 which may give lower values for LVM than reported in previous studies using steady-state-free-precession MRI. 64, 65 Thus, a separate study, involving all 14 centres, is being conducted prior to patient inclusion in the TELMAR trial in order to define the normal range of MRI data in an age-matched population more accurately.The same MRI protocol as will be implemented in the TELMAR trial was used in 147 healthy volunteers, 19-74 years of age, without evidence of any cardiovascular disease, including hypertension. The images underwent a centralised reading (CIRCLE Institute GmbH, Berlin, Germany) by the same readers using the same algorithms as will be applied in the TELMAR trial. Inclusion of these subjects started in September 2002; the results of this data collection resulted in threshold values for LVMI(H) to define LVH of 0.8 g/cm for women and 1.1 g/cm for men.
Safety evaluations
The safety evaluation will be performed on all patients receiving at least one dose of active treatment (the safety population). Endpoints pertaining to safety will be descriptively presented and will include all adverse events, adverse events leading to discontinuation, adverse events by intensity, serious adverse events and drug-related adverse events. Adverse events will be collected according to an adverse event recording form, which will prompt for possible effects related to study medication, such as hypotension, dizziness and bradycardia.
Safety and tolerability will also be assessed by measurement of changes from baseline in physical examinations. Standard laboratory tests (clinical chemistry, haematology, urinalysis and pregnancy tests for women of child-bearing age) will be conducted at each site and the proportion of patients outside the reference ranges will be summarised.
Statistical considerations Sample size calculation
Sample size calculations were performed with the following assumptions. First, the reduction of the LVMI will be between 8% and 17%, according to data reported by Thürmann et al. 13 The corresponding standard deviations in that study were 12-17%.The standard deviation for the percentage change of LVMI(H) from baseline as derived by MRI, however, is about 50% lower than that derived by echocardiography. 48 Thus, it is expected that the standard deviation for the percentage change from baseline in LVMI(H) will be approximately 10%.
Using an estimate for the standard deviation of 10% and a non-inferiority margin of 5%, a sample size of 64 patients per treatment regimen would have 80% power at the 2.5% (one-sided) level of significance to show non-inferiority of telmisartan versus metoprolol if both treatments are equal. The same power will be achieved to show superiority of telmisartan if the effect of telmisartan is 5% greater than metoprolol. Thus, a total number of 128 patients will be needed for the analysis.
Assuming that approximately 10% of all randomised patients will discontinue the study prematurely or will not have a final MRI that is adequate for evaluation, it is anticipated that a total of 140 patients will need to be randomised (70 patients per treatment arm). Additionally, taking into account that approximately 30% of patients will not fulfill the entry criteria based on MRI and ABPM, it is expected that about 200 patients will need to be enrolled into the run-in period.
Primary endpoint
The primary objective is to show that telmisartan is not inferior to metoprolol with respect to the ESWS = RR syst x 0.133 x +1
Where RR syst denotes SBP during the MRI procedure ESV denotes end-systolic volume as measured by three-dimensional MRI, and LVM denotes left ventricular mass as measured by three-dimensional MRI. An absolute difference of 5% is the maximum difference between the treatment means that is considered to have no clinical importance (i.e., the limit of non-inferiority).
If the upper limit of the two-sided 95% confidence interval for the least square mean difference between both treatments ([telmisartan baseline -telmisartan follow-up ] -[metoprolol baseline -metoprolol follow-up ]) lies below 5%, then the null hypothesis of inferiority will be rejected and it will be decided that the mean percentage change from baseline in LVMI(H) for telmisartan is not inferior to metoprolol.This decision procedure is equivalent to a test of the one-sided hypothesis at the 2.5% level. If non-inferiority of telmisartan in comparison with metoprolol is established, a superiority test will be performed. If the upper limit of the two-sided 95% confidence interval for the least square mean difference not only lies below 5%, but also below zero, then telmisartan will be considered significantly superior to metoprolol.
The primary analysis will use both the full analysis set (FAS), based on the intention-to-treat (ITT) principle, and the per-protocol (PP) analysis set, since both have equal importance and should lead to similar conclusions for a robust interpretation. The analysis to demonstrate superiority will be performed on the FAS only. The FAS population for the primary analysis will consist of all randomised patients who received at least one dose of active medication and had evaluable baseline and followup LVMI(H) data from MRI. The PP population is a subset of the FAS population, consisting of all patients with no relevant protocol violations.The relevance of protocol deviations will be assessed while maintaining blindness of treatment allocation.
As LVMI(H) determination by MRI is standardised in this study and there will be an independent central reader of all MRI scans, centre-related issues are not expected to be an important blocking factor and will not be included in the primary analysis model. However, in order to assess whether the treatment effect is homogeneous across study sites, the centre effect and treatmentby-centre interaction will be explored by adding these terms as factors in the model used for the primary analysis.To account for differences in the number of patients per treatment group and/or centre, the Type 2 sums of squares in the analysis of covariance (ANCOVA) model for estimates of treatment differences will be applied. In the event that several centres randomise fewer than four patients, these subjects will be pooled into a smaller set of 'centres'.The size of pooled 'centres' will not exceed the size of unpooled centres.
Secondary endpoints
The FAS based on the ITT principle will be used for all secondary analyses, which will be performed using a two-sided p=0.05 level of significance in an exploratory sense. The percentage change from baseline in LVMI related to the body surface area [LVMI(BSA)], as well as the absolute changes from baseline in LVMI(H) and LVMI(BSA) will be analysed using the same approach as for the primary analysis.
The secondary endpoints associated with ventricular function as measured by MRI and associated with BP measurements will also be evaluated using the same statistical methods/models as described for the primary endpoint. Responder rates will be evaluated using Mantel-Haenszel test. Correlation between change in LVMI and change in BP will be compared between the treatment groups.
Baseline demographics and baseline disease data will be summarised descriptively for each treatment group as well as the total study population.
Organisational structure
Steering committee An international steering committee was formed that approved the study design and the protocol in May 2002. Meetings are scheduled during the trial to ensure adherence to the study goals.
Institutional Review Board, randomisation and timeline
The study design was approved for implementation by an Institutional Ethical Committee (Ethikkommission der Landesaerztekammer Rheinland-Pfalz) and was approved by Institutional Review Boards at the other study institutions. Investigators will be blinded to the patients' treatment assignments. Investigators will obtain individual patient data (history heart rate, BP) as part of regular monitoring visits to ensure patient safety. Patients have been enrolled since November 2002. 
